Allogene Therapeutics

Allogene Therapeutics is a biotechnology company focused on developing allogeneic CAR T (AlloCAR T) cell therapies for cancer treatment. They make money by advancing their proprietary pipeline of therapies through clinical trials and securing partnerships and collaborations within the pharmaceutical industry. Founded in 2017 by former executives of Kite Pharma, the company has rapidly progressed, leveraging its expertise in gene editing and immuno-oncology to create off-the-shelf treatments that aim to be more accessible and scalable than autologous CAR T therapies.

Recent Posts by Allogene Therapeutics

1-20 of 88